Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer

Jing Tian, Yuangzeng Min, Zachary Rodgers, Xiaomeng Wan, Hui Qiu, Yu Mi, Xi Tian, Kyle T. Wagner, Joseph M. Caster, Yanfei Qi, Kyle Roche, Tian Zhang, Jianjun Cheng, Andrew Z. Wang

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

The combination chemotherapy regimen of cisplatin (CP) and docetaxel (DTX) is effective against a variety of cancers. However, combination therapies present unique challenges that can complicate clinical application, such as increases in toxicity and imprecise exposure of tumors to specific drug ratios that can produce treatment resistance. Drug co-encapsulation within a single nanoparticle (NP) formulation can overcome these challenges and further improve combinations' therapeutic index. In this report, we employ a CP prodrug (CPP) strategy to formulate poly(lactic-co-glycolic acid)–poly(ethylene glycol) (PLGA–PEG) NPs carrying both CPP and DTX. The dually loaded NPs display differences in drug release kinetics and in vitro cytotoxicity based on the structure of the chosen CPP. Furthermore, NPs containing both drugs showed a significant improvement in treatment efficacy versus the free drug combination in vivo.

Original languageEnglish (US)
Pages (from-to)1301-1307
Number of pages7
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume13
Issue number3
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Keywords

  • Cisplatin prodrugs
  • Combination therapy
  • Docetaxel
  • Drug delivery
  • PLGA–PEG

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer'. Together they form a unique fingerprint.

Cite this